Drugs / AS03A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06560151 | Aug 2024 → Jan 2025 | influenza | Biomedical Advanced Research and Development Authority | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04789577 Comparator | Mar 2021 → Sep 2022 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AS03A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04789577 ↗ |
| Known as | AS03 | “AS03A is the adjuvant AS03®.” NCT06560151 ↗ |